About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 37155 record(s)
Req # A-2022-001166
All emails to and from Twitter and Facebook employees since Jan 1, 2019.Organization: Health Canada
May 2023
Req # A-2022-001494
The draft Product Monograph included in the New Drug Submission (NDS) for Captopril at the time of screening, any and all Notices of Deficiency, Notices of Non-Compliance and clarifaxes associated with Health Canada's review of the NDS.Organization: Health Canada
May 2023
Req # A-2022-001499
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24 for the medicinal ingredient aprepitant. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for aprepitant which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24.Organization: Health Canada
May 2023
Req # A-2022-001509
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24 for the medicinal ingredients methotrexate & methotrexate sodium. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for methotrexate & methotrexate sodium which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24.Organization: Health Canada
May 2023
Req # A-2021-002081
Adverse Drug Reactions (ADRs) for MORPHINE. Report numbers: 000973791, 000975736, 000976090. ADR for HEPARIN. Report number: 000974721.Organization: Health Canada
May 2023
Req # A-2022-000218
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-103330-693.Organization: Health Canada
May 2023
Req # A-2022-000241
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-102751-611.Organization: Health Canada
May 2023
Req # A-2022-000284
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-102891-541.Organization: Health Canada
May 2023
Req # A-2022-000341
Adverse Drug Reactions (ADRs) for VENOFER. Report numbers: 000987532, 000987579, 000988287, 000988830, 000990245.Organization: Health Canada
May 2023
Req # A-2022-000410
Adverse Drug Reactions (ADRs) for Heparin. Report numbers: 000988941, 000988974, 000989212, 000989214.Organization: Health Canada
May 2023